Aaron,
I wonder if we will see PLE results at all (or if we do, they may be played down).
My sense is PLE is plan B for Clinuvel at this point.
It is all about orhpan indications. Why? See Cerezyme (Gauchers Disease) to understand why. It is based on:
- small number of patients (5,000 in the case of Gauchers)
- extremely high price for the drug (US$200,000 in case of Gauchers / Cerezye)
- high govt subsidies
Clinuvel can make substantial earnings from orphan indications, and can do so very quickly. It is the quickest route to market, and earnings.
PLE is a broad based market strategy. It is incompatible with an orphan approach - gestation period is longer, pricing strategy different (because low govt subsidies for broader application).
My sense is PLE is plan B at this stage. They'll pursue it further down the track once they have they are up and running with their orphan indications.
- Forums
- ASX - By Stock
- CUV
- volume in europe, a precursor?
volume in europe, a precursor?, page-2
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CUV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$13.19 |
Change
-0.380(2.80%) |
Mkt cap ! $660.5M |
Open | High | Low | Value | Volume |
$13.46 | $13.57 | $13.13 | $1.075M | 81.32K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 164 | $13.19 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.29 | 286 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 164 | 13.190 |
1 | 758 | 13.160 |
1 | 286 | 13.150 |
2 | 956 | 13.130 |
2 | 1036 | 13.110 |
Price($) | Vol. | No. |
---|---|---|
13.290 | 286 | 1 |
13.310 | 286 | 1 |
13.330 | 286 | 1 |
13.350 | 286 | 1 |
13.500 | 601 | 2 |
Last trade - 16.10pm 22/08/2024 (20 minute delay) ? |
Featured News
CUV (ASX) Chart |
The Watchlist
SS1
SUN SILVER LIMITED
Gerard O'Donovan, Executive Director
Gerard O'Donovan
Executive Director
SPONSORED BY The Market Online